Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Lung Neoplasms 7Ovarian Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Fallopian Tube Neoplasms 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Pancreatic Neoplasms 3Mouth Neoplasms 3Endometrial Neoplasms 3Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Oropharyngeal Neoplasms 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Mycosis Fungoides 2Multiple Myeloma 2Melanoma 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoid Interstitial Pneumonia 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Colonic Neoplasms 2Carcinoma 2Brenner Tumor 2Breast Neoplasms 2Adenocarcinoma of Lung 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1

Interventions

olaparib 1liposomal doxorubicin 1durvalumab 1cediranib 1Topotecan 1Taxes 1Specimen Handling 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Mucinous Adenocarcinoma × Disulfides × 30 days × Clear all
NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡